CSL has updated investors with a detailed presentation on the strategic rationale underpinning its recent acquisition of Vifor Pharma with the company anticipating its new division will deliver annual revenue growth above 10 per cent.
Latest Video
New Stories
-
Companies welcome November PBAC outcomes
December 23, 2024 - - Latest News -
The 'Dispatched' Podcast - 'This draws a line through everything and it's not good'
December 22, 2024 - - Podcast -
'Found irregularities and anomalies in the instruments of delegation from the minister'
December 20, 2024 - - Latest News -
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 - - Australian Biotech -
Wholesalers secure five-year agreement with the Government
December 19, 2024 - - Latest News -
When the Government funds a health technology, the community makes certain assumptions
December 19, 2024 - - Latest News -
If this decision to undermine the TGA reflects a policy decision, be transparent about it
December 18, 2024 - - Latest News